{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:52:11Z","timestamp":1782489131213,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","award":["10070012010003"],"award-info":[{"award-number":["10070012010003"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ijrobp.2025.12.052","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:07:47Z","timestamp":1767917267000},"page":"1008-1017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Toxicity and Treatment Completion of Neoadjuvant FOLFOXIRI and Chemoradiotherapy in Patients With High-Risk Locally Advanced Rectal Cancer: A Secondary Outcome Analysis of the MEND-IT Trial"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6684-0101","authenticated-orcid":false,"given":"Evi","family":"Banken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene E.G.","family":"van Hellemond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike M.U.","family":"Peulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Nederend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst J.A.","family":"Steller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Willem B.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend G.J.","family":"Aalbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tineke E.","family":"Buffart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"Werter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joeri A.J.","family":"Douma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne G.","family":"Bloemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus W.A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.12.052_bib0001","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.annonc.2025.05.528","article-title":"Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Hofheinz","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0002","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clon.2022.11.011","article-title":"Watch-and-wait is an option in rectal cancer patients: From controversy to common clinical practice","volume":"35","author":"Grotenhuis","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0003","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/DCR.0000000000000547","article-title":"Treatment of locally recurrent rectal carcinoma in previously (chemo)irradiated patients: A review","volume":"59","author":"van der Meij","year":"2016","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0004","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","article-title":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial","volume":"12","author":"van Gijn","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0005","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","article-title":"Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years","volume":"30","author":"Sauer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0006","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.2013.54.3769","article-title":"Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: Updated results of the CAO\/ARO\/AIO-94 trial","volume":"32","author":"Fokas","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0007","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1056\/NEJMoa010580","article-title":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer","volume":"345","author":"Kapiteijn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0008","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00000478-200203000-00009","article-title":"Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: Not one millimeter but two millimeters is the limit","volume":"26","author":"Nagtegaal","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0009","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1200\/JCO.18.00032","article-title":"Neoadjuvant (chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: Results of the Multicenter Lateral Node Study of patients with low cT3\/4 rectal cancer","volume":"37","author":"Ogura","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0010","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/bjc.2017.99","article-title":"A meta-analysis comparing the risk of metastases in patients with rectal cancer and MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases","volume":"116","author":"Siddiqui","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0011","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/bjs.10949","article-title":"Prognostic implications of MRI-detected lateral nodal disease and extramural vascular invasion in rectal cancer","volume":"105","author":"Schaap","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0012","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1097\/SLA.0000000000005755","article-title":"Negative prognostic impact of tumor deposits in rectal cancer: A national study cohort","volume":"278","author":"Agger","year":"2023","journal-title":"Ann Surg"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0013","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2019.2172","article-title":"Lateral nodal features on restaging magnetic resonance imaging associated with lateral local recurrence in low rectal cancer after neoadjuvant chemoradiotherapy or radiotherapy","volume":"154","author":"Ogura","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0014","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","article-title":"Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: A 5-year follow-up of the RAPIDO trial","volume":"278","author":"Dijkstra","year":"2023","journal-title":"Ann Surg"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0015","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0016","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.3390\/cancers12123655","article-title":"Impact of total neoadjuvant therapy vs. standard chemoradiotherapy in locally advanced rectal cancer: A systematic review and meta-analysis of randomized trials","volume":"12","author":"Riesco-Martinez","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0017","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): A randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0018","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1200\/JCO.21.01667","article-title":"Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)","volume":"40","author":"Jin","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0019","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/annonc\/mdz186","article-title":"Long-course preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: Long-term results of the randomized Polish II study","volume":"30","author":"Cisel","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0020","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.clon.2021.06.006","article-title":"Intensified total neoadjuvant therapy in patients with locally advanced rectal cancer: A phase II trial","volume":"33","author":"De Felice","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.5445","article-title":"Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: Long-term results of the CAO\/ARO\/AIO-12 randomized clinical trial","volume":"8","author":"Fokas","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0022","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1186\/s12885-022-09947-w","article-title":"Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk (\u201cugly\u201d) locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT)","volume":"22","author":"van den Berg","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0023","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/bjs.5917","article-title":"Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer","volume":"95","author":"Smith","year":"2008","journal-title":"Br J Surg"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0024","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: Long-term results","volume":"240","author":"Habr-Gama","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0025","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1200\/JCO.2011.37.7176","article-title":"Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer","volume":"29","author":"Maas","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0026","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): An international multicentre registry study","volume":"391","author":"van der Valk","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0027","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0. Accessed September 1, 2025. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0028","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijrobp.2023.07.043","article-title":"Compliance and toxicity of total neoadjuvant therapy for rectal cancer: A secondary analysis of the OPRA trial","volume":"118","author":"Verheij","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0029","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andre","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0030","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1200\/JCO.2011.36.4539","article-title":"Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses","volume":"29","author":"Yothers","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0031","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3390\/jcm9082400","article-title":"Long-term prevalence of sensory chemotherapy-induced peripheral neuropathy for 5 years after adjuvant FOLFOX chemotherapy to treat colorectal cancer: A multicenter cross-sectional study","volume":"9","author":"Selvy","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0032","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/0284186X.2018.1556804","article-title":"Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy","volume":"58","author":"Soveri","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0033","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S1470-2045(15)00159-X","article-title":"Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO\/ARO\/AIO-04 study): Final results of the multicentre, open-label, randomised, phase 3 trial","volume":"16","author":"Rodel","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0034","doi-asserted-by":"crossref","first-page":"e1555","DOI":"10.1002\/onco.13824","article-title":"Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: A systematic review and meta-analysis","volume":"26","author":"Liu","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ijrobp.2025.12.052_bib0035","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.19.00308","article-title":"Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO\/ARO\/AIO-12","volume":"37","author":"Fokas","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 17","key":"10.1016\/j.ijrobp.2025.12.052_bib0036","volume":"41","author":"Schrag","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626000180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626000180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:30:17Z","timestamp":1782487817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626000180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0360301626000180"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.12.052","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity and Treatment Completion of Neoadjuvant FOLFOXIRI and Chemoradiotherapy in Patients With High-Risk Locally Advanced Rectal Cancer: A Secondary Outcome Analysis of the MEND-IT Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.12.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}